An inhaler (puffer, spray or pump) is a medical device that is used for delivering medication into the body via lungs. It is used for releasing medication in the body to treat respiratory diseases such as bronchitis, asthma, allergic rhinitis, Chronic Obstructive Pulmonary Disorder (COPD), pneumonia, and sinusitis. All these diseases can significantly restrain the physical activities of the individual. Orally inhaled and nasal drug products (OINDPs) are the products which include metered dose (MDIs), dry powder inhalers (DPIs), nasal sprays and nebulizers. According to FDA, respiratory inhalers are classified under Class II medical devices. All inhaled products have to undergo mandatory test for extractables, leachables and microbial contaminants. Specific tests for OINDPs include aerodynamic particle size distribution (APSD) and delivered dose uniformity (DDU). These tests are regarded as key parameters for assessing performance of the OINDPs. In addition, nasal sprays and MDIs are supplemented by tests to monitor the performance of the actuator and metering valve such as plume geometry and spray pattern.
Restraints of the Global Respiratory Inhaler Market
Patients often struggle while using respiratory inhalers due to complex functioning, if not taught properly by trained healthcare professionals, which drives patient to opt for other route of administration. Improper use of inhalers reduces its effectiveness drastically, so, patients need to be monitored at regular intervals and inhalers need to be prescribed based on individual technical abilities. This factor is expected to restrain growth of the market up to certain extent.
Key features of the study:
- This report provides in-depth analysis of the global Respiratory Inhaler Market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2019–2027), considering 2018, as the base year
- It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
- It profiles leading players in the global Respiratory Inhaler Market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, strategies, and future plans
- Key companies covered as a part of this study include AstraZeneca plc, Beximco Pharmaceuticals Ltd., Boehringer Ingelheim GmbH, Cipla Ltd., GlaxoSmithKline plc., Koninklijke Philips N.V., Merck & Co., Inc., OMRON Healthcare Europe B.V., PARI Medical Holding, and Teva Pharmaceutical Industries Ltd.
- Insights from this report would allow marketers and the management authorities of companies to make informed decision regarding future product launches, technology up-gradation, market expansion, and marketing tactics
- The global Respiratory Inhaler Market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the market.
Detailed Segmentation
- Global Respiratory Inhaler Market, By Product Type:
- Dry Powder Inhaler
- Metered Dose Inhaler
- Nebulizer
- Ultrasonic Nebulizer
- Compressed Air Nebulizer
- Mesh Nebulizer
- Global Respiratory Inhaler Market, By Technology:
- Manually Operated Inhaler Devices
- Digitally Operated Inhaler Devices
- Global Respiratory Inhaler Market, By Disease Indication:
- Asthma
- COPD
- Pulmonary Arterial Hypertension
- Others
- Global Respiratory Inhaler Market, By Geography:
- North America
- By Product Type
- Dry Powder Inhaler
- Metered Dose Inhaler
- Nebulizer
- Ultrasonic Nebulizer
- Compressed Air Nebulizer
- Mesh Nebulizer
- By Technology:
- Manually Operated Inhaler Devices
- Digitally Operated Inhaler Devices
- By Disease Indication
- Asthma
- COPD
- Pulmonary Arterial Hypertension
- Others
- By Country:
- Europe
- By Product Type
- Dry Powder Inhaler
- Metered Dose Inhaler
- Nebulizer
- Ultrasonic Nebulizer
- Compressed Air Nebulizer
- Mesh Nebulizer
- By Technology:
- Manually Operated Inhaler Devices
- Digitally Operated Inhaler Devices
- By Disease Indication
- Asthma
- COPD
- Pulmonary Arterial Hypertension
- Others
- By Country:
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Product Type
- Dry Powder Inhaler
- Metered Dose Inhaler
- Nebulizer
- Ultrasonic Nebulizer
- Compressed Air Nebulizer
- Mesh Nebulizer
- By Technology:
-
- Manually Operated Inhaler Devices
- Digitally Operated Inhaler Devices
- By Disease Indication
- Asthma
- COPD
- Pulmonary Arterial Hypertension
- Others
- By Country:
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- By Product Type
- Dry Powder Inhaler
- Metered Dose Inhaler
- Nebulizer
- Ultrasonic Nebulizer
- Compressed Air Nebulizer
- Mesh Nebulizer
- By Technology:
- Manually Operated Inhaler Devices
- Digitally Operated Inhaler Devices
- By Disease Indication
- Asthma
- COPD
- Pulmonary Arterial Hypertension
- Others
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East:
- By Product Type
- Dry Powder Inhaler
- Metered Dose Inhaler
- Nebulizer
- Ultrasonic Nebulizer
- Compressed Air Nebulizer
- Mesh Nebulizer
- By Technology:
- Manually Operated Inhaler Devices
- Digitally Operated Inhaler Devices
- By Disease Indication
- Asthma
- COPD
- Pulmonary Arterial Hypertension
- Others
- By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
- By Product Type
- Dry Powder Inhaler
- Metered Dose Inhaler
- Nebulizer
- Ultrasonic Nebulizer
- Compressed Air Nebulizer
- Mesh Nebulizer
- By Technology:
- Manually Operated Inhaler Devices
- Digitally Operated Inhaler Devices
- By Disease Indication
- Asthma
- COPD
- Pulmonary Arterial Hypertension
- Others
- By Country/Region:
- Central Africa
- South Africa
- North Africa
- Company Profiles
- AstraZeneca plc.*
- Company Overview
- Product Portfolio
- Financial Performance
- Key Strategies
- Recent Developments
- Beximco Pharmaceuticals Ltd.
- Boehringer Ingelheim GmbH
- Cipla Ltd.
- GlaxoSmithKline plc.
- Koninklijke Philips N.V.
- Merck & Co., Inc.
- OMRON Healthcare Europe B.V.
- PARI Medical Holding
- Teva Pharmaceutical Industries Ltd.
“*” marked represents similar segmentation in other categories in the respective section.
